GAITHERSBURG, Md., Feb. 20, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
|Date:||Monday, February 27, 2017|
|Time:||4:30 p.m. U.S. Eastern Time (ET)|
|Dial-in number:||(877) 212-6076 (Domestic) or (707) 287-9331 (International)|
|Webcast:||www.novavax.com, “Investors”/ “Events”|
Conference call and webcast replay:
|Dates:||Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017|
|Dial-in number:||(855) 859-2056 (Domestic) or (404) 537-3406 (International)|
|Webcast:||www.novavax.com, “Investors”/ “Events”, until April 30, 2017|
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations firstname.lastname@example.org 240-268-2000 Westwicke Partners John Woolford email@example.com 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. firstname.lastname@example.org 212-845-4271